Rising prevalence of lifestyle associated accompanied with chronic disorders in women is majorly proliferating the women’s health therapeutics market size over the study time frame. Furthermore, increasing healthcare investment to diagnose infectious and cancer disease at early stage, pregnancy related complexities, and introduction of innovative & effective drugs is likely to propel industry size.
The global Women’s Health Therapeutics Market is expected to be around US$ 247 billion in 2028 a CAGR of 8.5%.
Increasing awareness relevant to menopause, infections, osteoporosis, and cancer is predicted to accelerate the industry growth. In addition, launch of new drug therapies by major industry players will further contribute in expansion of industry size over the next seven years. For instance, in March 2017, the U.S. Food and Drug Administration (FDA) approved Zejula by TESARO, that will be used for treating advanced ovarian cancer.
Global women’s health therapeutics market is segmented based on the type as, Infection, Pregnancy, and Oncology. Global women’s health therapeutics market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional women’s health therapeutics market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global women’s health therapeutics market share consists of several players including Mylan, GlaxoSmithKline, Bayer; Novartis, Pfizer; TESARO, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, AstraZeneca, and Teva Pharmaceutical.
The Women’s Health Therapeutics Market has been segmented as below:
Women’s Health Therapeutics Market, By Type
Women’s Health Therapeutics Market, By Region
The report covers:
Report scope:
The global women’s health therapeutics market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Mylan, GlaxoSmithKline, Bayer; Novartis, Pfizer; TESARO, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, AstraZeneca, and Teva Pharmaceutical.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. High prevalence of infectious diseases among women
4.2.2. Growing awareness
4.3. Restraints
4.3.1. High cost of therapies
4.4. Opportunities
4.4.1. Increasing investments
4.4.2. Introduction of new drug therapies
4.5. Challenges
4.5.1. Stringent regulations
5. Women’s Health Therapeutics Market, By Product
5.1. Key Points
5.2. Infection
5.3. Pregnancy
5.4. Oncology
5.4.1. Cervical Cancer
5.4.2. Uterine Cancer
5.4.3. Ovarian Cancer
5.4.4. Vaginal & Vulvar Cancer
6. Competitive Landscape
6.1. Introduction
6.2. Recent Developments
6.2.1. Mergers & Acquisitions
6.2.2. New Product Developments
6.2.3. Portfolio/Production Capacity Expansions
6.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
6.2.5. Others
7. Company Profile
7.1. Mylan
7.1.1. Company Overview
7.1.2. Product/Service Landscape
7.1.3. Financial Overview
7.1.4. Recent Developments
7.2. GlaxoSmithKline
7.2.1. Company Overview
7.2.2. Product/Service Landscape
7.2.3. Financial Overview
7.2.4. Recent Developments
7.3. Bayer
7.3.1. Company Overview
7.3.2. Product/Service Landscape
7.3.3. Financial Overview
7.3.4. Recent Developments
7.4. Novartis
7.4.1. Company Overview
7.4.2. Product/Service Landscape
7.4.3. Financial Overview
7.4.4. Recent Developments
7.5. Pfizer
7.5.1. Company Overview
7.5.2. Product/Service Landscape
7.5.3. Financial Overview
7.5.4. Recent Developments
7.6. TESARO
7.6.1. Company Overview
7.6.2. Product/Service Landscape
7.6.3. Financial Overview
7.6.4. Recent Developments
7.7. Bristol-Myers Squibb Company
7.7.1. Company Overview
7.7.2. Product/Service Landscape
7.7.3. Financial Overview
7.7.4. Recent Developments
7.8. F. Hoffmann-La Roche
7.8.1. Company Overview
7.8.2. Product/Service Landscape
7.8.3. Financial Overview
7.8.4. Recent Developments
7.9. AstraZeneca
7.9.1. Company Overview
7.9.2. Product/Service Landscape
7.9.3. Financial Overview
7.9.4. Recent Developments
7.10. Teva Pharmaceutical
7.10.1. Company Overview
7.10.2. Product/Service Landscape
7.10.3. Financial Overview
7.10.4. Recent Developments
The Women’s Health Therapeutics Market has been segmented as below:
Women’s Health Therapeutics Market, By Type
Women’s Health Therapeutics Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
